- After the markets closed on Tuesday, VistaGen Therapeutics Inc (NASDAQ:VTGN) reported a Q3 FY23 net loss of $(9.8) million or $(0.05) per share, narrower than the consensus of $(0.07).
- William Blair estimated an EPS loss of $(0.06).
- VistaGen says that it is not advisable to resume the PALISADE-2 study after failed Phase 3 PALISADE-1 trial of PH94B for the acute treatment of social anxiety disorder (SAD).
- Also Read: Vistagen Strengthens Its Neurology-Focused Pipeline With Pherin Pharma Acquisition.
- The company now plans to meet with the FDA to discuss the path forward for the program.
- A preliminary analysis of data from the PALISADE open-label safety study of acute, as-needed use of PH94B suggests that repeated, as-needed usage may improve symptoms of SAD.
- While it is encouraging to see VistaGen continue developing PH94B in anxiety disorders, the analyst awaits further details on these data before revisiting views on the program.
- William Blair says that given the uncertainty around the path forward for PH94B and extended timelines to potential commercialization, it rates shares Market Perform.
- Price Action: VTGN shares are down 18.75% at $0.2119 on the last check Wednesday.
FTC Solar And 2 Other Stocks Under $5 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 300 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
